scholarly journals Recurrent Unprovoked Deep Vein Thromboses in the Setting of Sarcoidosis

Cureus ◽  
2021 ◽  
Author(s):  
Brinda Basida ◽  
Maryam B Haider ◽  
Joshua Barbosa
Keyword(s):  
Deep Vein ◽  
Deep Vein Thromboses

scholarly journals Efficacy of Dabigatran for Dissolving Deep Vein Thromboses in Outpatients With a Deteriorated General Condition

2015 ◽  
Vol 56 (4) ◽  
pp. 395-399 ◽  
Author(s):  
Tadashi Fujino ◽  
Yukiko Yamazaki ◽  
Akiko Yamazaki ◽  
Takayuki Kabuki ◽  
Shunsuke Kiuchi ◽  
...  
Keyword(s):  
General Condition ◽  
Deep Vein ◽  
Deep Vein Thromboses

Diagnostic visualization

1979 ◽  
Vol 292 (1390) ◽  
pp. 177-185
Keyword(s):  
Nuclear Medicine ◽  
Population Screening ◽  
Cerebral Abscess ◽  
Pulmonary Emboli ◽  
Radiological Investigation ◽  
Diagnostic Modalities ◽  
Deep Vein ◽  
Medical Situation ◽  
Deep Vein Thromboses

The concept of total diagnostic visualization is based on the presumption that on the whole no single radiological investigation is self-sufficient and that it should be considered in relation to all other available diagnostic modalities. Although nuclear medicine techniques are expanding rapidly, especially for functional investigations, and have the advantage of non-invasiveness and sensitivity (which are ideal requisites for population screening), they remain relatively non-specific. This paper attempts to show how improved specificity may be effected by means of cross-modality techniques, and this is discussed in relation to the detection of cerebral abscess, focal hepatic defects, pulmonary emboli and deep-vein thromboses. An example of how the technique can be used in an engineering situation, namely to discover defects in concrete, is also considered and related to the philosophy outlined in the medical situation. ‘Prove all things; hold fast that which is good.’ (1 Thessalonians 5:21)

288Thrombotic events in bleeding patients treated with andexanet alpha: an ANNEXA-4 sub-study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J Beyer-Westendorf ◽  
P Yue ◽  
M Crowther ◽  
J W Eikelboom ◽  
C M Gibson ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Median Time ◽  
Major Bleeding ◽  
Oral Anticoagulation ◽  
Thrombotic Event ◽  
Thrombotic Risk ◽  
Number Of Patients ◽  
Fxa Inhibitor ◽  
Deep Vein ◽  
Deep Vein Thromboses

Abstract Background/Introduction Andexanet alfa (“andexanet”) was developed as a specific reversal agent for patients with major bleeding while using factor Xa (FXa) inhibitors. While thrombotic events (TEs) have been reported in patients receiving andexanet, the scope, nature, and timing of these events have not been fully characterized. Purpose The ANNEXA-4 study was a prospective, single-arm, open-label clinical trial that evaluated the safety and efficacy of andexanet in patients with acute major bleeding. In this secondary analysis, the occurrence of TEs was investigated. Methods Patients presenting with acute major bleeding within 18 hours after their last dose of FXa inhibitor were treated with andexanet. Safety outcomes, including TEs (reviewed by an adjudication committee), were evaluated at 30 days. Results Among 352 patients treated with andexanet, 34 (9.7%) experienced one or more TEs (Table). Strokes and deep vein thromboses were the most frequent TE types. Compared to patients with arterial TEs, patients with venous TEs were more likely to have been originally anticoagulated for venous thromboembolism. Median time to first TE was 10.5 days (Figure); time to event was shorter for arterial TEs than for venous TEs. TEs were nonfatal for most patients. Subgroups by age, bleed type, baseline anti-fXa activity, FXa inhibitor dose, and andexanet dose were not associated with the occurrence of TEs. Of the 34 TE patients, 26 (76.4%) had TEs before restart of any (full or prophylactic) anticoagulation; all first TEs occurred in patients not receiving oral anticoagulation. No TEs occurred after resumption of oral anticoagulation (N=100). Table 1. Thrombotic event characteristics Characteristic Result (n/N [%]) TE type   Strokes 14/352 (4.0%)   Deep vein thromboses 13/352 (3.7%)   Myocardial infarctions 7/352 (2.0%)   Pulmonary embolisms 5/352 (1.4%)   Transient ischemic attacks 1/352 (0.3%) Bleed type   Intracranial 23/227 (10.1%)   Gastrointestinal 7/90 (7.8%)   Other 4/35 (11.4%) Arterial TEs   Anticoagulated for AF 17/22 (77.3%)   Anticoagulated for VTE 6/22 (27.3%) Venous TEs   Anticoagulated for AF 11/18 (61.1%)   Anticoagulated for VTE 8/18 (44.4%)   Median time to first TE 10.5 days   Arterial 6 days   Venous 15 days Outcome   Fatal 7/34 (20.6%)   Nonfatal 27/34 (79.4%) AF = atrial fibrillation; n = number of patients with TEs; N = total number of patients for each characteristic; TE = thrombotic event; VTE = venous thromboembolism. Figure 1. Thrombotic Events Over Time Conclusions In patients with FXa inhibitor-associated acute major bleeding treated with andexanet, TEs occurred a rate not unexpected given the high thrombotic risk of the population. No factors predictive of TEs were identified. Resumption of anticoagulation was associated with fewer TEs. Acknowledgement/Funding Study funded by Portola Pharmaceuticals, Inc.

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 128-128 ◽  
Author(s):  
Fatima H. Karzai ◽  
Bamidele Adesunloye ◽  
Yangmin M. Ning ◽  
Ravi Amrit Madan ◽  
James L. Gulley ◽  
...  
Keyword(s):  
Median Number ◽  
Phase Iii ◽  
Pulmonary Emboli ◽  
Toxicity Profile ◽  
Improve Outcome ◽  
Phase Iii Trials ◽  
Combination Studies ◽  
Deep Vein ◽  
Clinical Trial Information ◽  
Deep Vein Thromboses

128 Background: We have recently completed accrual of 63 patients (pts) to our study combining lenalidomide (L), with bevacizumab (B), docetaxel (D), and prednisone (P) (ART-P). Due to the lack of improved survival and the increased toxicity of anti-angiogenic docetaxel combinations in the MAINSAIL and CALGB 90410 trials we attempted to contrast and compare our studies with the failed phase III trials. Methods: Among the first 52 pts on the ART-P, 3 received L 15 mg daily, 3 had 20 mg daily, and the rest had 25 mg daily for 14 days of every 21−day cycle (C). We later enrolled 11 more pts at L 15 mg. All pts received D 75 mg/m2 and B 15 mg/kg on day 1 with P 10 mg and enoxaparin daily throughout each C. Pegfilgrastim was given on day 2. Patients on CALGB 90410 received D 75 mg/m2 and B 15 mg/kg on day 1 with P 10 mg and on MAINSAIL received D 75 mg/m2, L 25 mg daily for 14 days of every 21−day cycle with daily P. Patients on CALGB 90410 and MAINSAIL did not receive enoxaparin or pegfilgrastim prophylactically. Results: Median number of Cs in ART-P was 16 (3−38). PFS was 22 months and median OS has not been reached. Pts with measurable disease had 1 CR and 25 PR (86.7% RR). Two patients (3%) had deep vein thromboses. Of 1,219 cycles given, 14 cycles were complicated by febrile neutropenia (FN) (1.1%). There were no treatment related deaths. In comparison, median number of Cs in MAINSAIL L+DP arm was 6, with a PFS of 45 weeks and an OS of 77 weeks. Thirty-four pts (6.5%) developed pulmonary emboli and there were 2 deaths due to toxicity in the experimental arm. Nearly 12% of Cs were complicated by FN. In the experimental arm of CALGB 90410 trial, median OS was 22.6 months with median PFS of 9.9 months. Median number of Cs was 8, and 19 pts developed thromboses/emboli (3.6%). In addition, 7% of patients developed FN and treatment related deaths were reported at 4%. Conclusions: The use of supportive care allows the ART-P combination to be given for more cycles than were given in MAINSAIL and CALGB 90401 potentiating a longer PFS, RR and possibly OS with an improved toxicity profile. This data demonstrates the potential importance of supportive measures and is hypothesis generating for future combination studies. Clinical trial information: NCT00942578.

scholarly journals Varicella-associated Purpura Fulminans and Multiple Deep Vein Thromboses: A Case Report

2009 ◽  
Vol 76 (3) ◽  
pp. 165-168 ◽  
Author(s):  
Murat Dogan ◽  
Mehmet Acikgoz ◽  
Aydin Bora ◽  
Murat Basaranoglu ◽  
A. Faik Oner
Keyword(s):  
Case Report ◽  
Purpura Fulminans ◽  
Deep Vein ◽  
Deep Vein Thromboses

scholarly journals Asymptomatic deep vein thromboses in prolonged hospitalized COVID-19 patients

2021 ◽  
Author(s):  
Marko Lucijanic ◽  
Nevenka Piskac Zivkovic ◽  
Marija Ivic ◽  
Martina Sedinic ◽  
Boris Brkljacic ◽  
...  
Keyword(s):  
Deep Vein ◽  
Deep Vein Thromboses

Haemodilution in Venous Disease

1991 ◽  
Vol 6 (1) ◽  
pp. 31-36 ◽  
Author(s):  
M. Duruble ◽  
P. Ouvry
Keyword(s):  
Pressure Gradient ◽  
Success Rate ◽  
Rheological Properties ◽  
Venous Disease ◽  
Appropriate Treatment ◽  
Deep Vein ◽  
Deep Vein Thromboses

Postoperative deep vein thromboses (DVT) and post-phlebitic ulcers are usually caused by stasis of the blood. The flow of blood in a vein does not depend only on the pressure gradient. The rheological properties of the blood must also be considered. We therefore studied the effects of various degrees of intraoperative normovolemic haemodilution on the incidence of postoperative DVT. The results of these studies indicate that moderate intra- and post-operative haemodilution lessens the risk of DVT. Most post-phlebitic ulcers heal after appropriate treatment on an ambulatory basis. A certain number of these ulcers prove, however, to respond badly to the treatment; they are called resistant post-phlebitic ulcers. It seemed logical to increase patients' ability to combat stasis by adding the process of haemodilution to the classical treatment. A year after treatment finished, the success rate amounted to nearly 80%.

Sign in / Sign up

Export Citation Format

Share Document